Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).

Cancer communications (London, England)（2022）

引用 7|浏览39

暂无评分

摘要

Compared with docetaxel, sintilimab significantly improved the OS, PFS, and ORR of Chinese patients with previously treated locally advanced or metastatic sqNSCLC.

查看译文

关键词

Carcinoma, squamous cell,Immunotherapy,Non-small cell lung cancer,Randomized controlled trial,Sintilimab,Survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要